Advances in new drugs to for curing Hepatitis B and Hepatitis D announced at ILC 2021
For Immediate Release Media Release Advances in new drugs to for curing Hepatitis B and Hepatitis D announced at ILC 2021 Thursday 24 June 2021 (Geneva, Switzerland)-- Leading hepatology researchers announced important…
ILC 2021 opens with focus on impact of COVID-19 on global liver disease
For Immediate Release Media Release ILC 2021 opens with focus on impact of COVID-19 on global liver disease New data demonstrates that chronic liver disease increased the odds of COVID-19 death by 80% and Pfizer-BioNTech COVID-19…
Showcasing EU-funded projects at ILC 2021
Five EU-funded projects to explore at ILC 2021
2021 update on EASL Clinical Practice Guidelines on non-invasive techniques for the evaluation of liver disease and severity
Mark your calendars! On 22 of June 2021, the European Association for the Study of Liver disease (EASL) will be releasing the much-anticipated updated guidelines on the use of non-invasive techniques (NITs). These new…
EASL supports International NASH Day 2021: NASH Around the World
8 June 2021 EASL is delighted to be officially endorsing International NASH Day 2021: NASH Around the World, conducted by the Global Liver Institute (GLI), this Thursday, 10 June. Non-alcoholic steatohepatitis (NASH), the advanced form of non-alcoholic…
Discover the topics selected by the liver community for ILC 2021
Last December, we asked you, as members of the liver community, to tell us which topics you wanted to see featured in the ILC 2021 programme. We received numerous excellent suggestions and…
Honouring the European Week Against Cancer 2021, ending on World No Tobacco Day
31 May 2021 This European Week Against Cancer, EASL has contributed in many ways to tackling liver cancer: signing a joint-society statement, contributing to a White Paper, and taking part in several webinars.